Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 4.40
KYTH's Cash to Debt is ranked higher than
79% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.36 vs. KYTH: 4.40 )
KYTH' s 10-Year Cash to Debt Range
Min: 4.22   Max: No Debt
Current: 4.4

F-Score: 2
Z-Score: 8.16
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -127.73
KYTH's ROE (%) is ranked lower than
54% of the 792 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.26 vs. KYTH: -127.73 )
KYTH' s 10-Year ROE (%) Range
Min: -47.46   Max: -47.46
Current: -127.73

ROA (%) -93.99
KYTH's ROA (%) is ranked lower than
55% of the 811 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.06 vs. KYTH: -93.99 )
KYTH' s 10-Year ROA (%) Range
Min: -52.09   Max: -38.51
Current: -93.99

-52.09
-38.51
ROC (Joel Greenblatt) (%) -42555.98
KYTH's ROC (Joel Greenblatt) (%) is ranked lower than
56% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.08 vs. KYTH: -42555.98 )
KYTH' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -27136.04   Max: -3013.33
Current: -42555.98

-27136.04
-3013.33
» KYTH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

KYTH Guru Trades in Q3 2013

Steven Cohen Sold Out
» More
Q4 2013

KYTH Guru Trades in Q4 2013

RS Investment Management 243,300 sh (New)
Jim Simons 41,200 sh (New)
» More
Q1 2014

KYTH Guru Trades in Q1 2014

Jim Simons 116,400 sh (+182.52%)
RS Investment Management 288,700 sh (+18.66%)
» More
Q2 2014

KYTH Guru Trades in Q2 2014

Steven Cohen 15,200 sh (unchged)
Jim Simons Sold Out
RS Investment Management 283,181 sh (-1.91%)
» More
» Details

Insider Trades

Latest Guru Trades with KYTH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 8.21
KYTH's P/B is ranked higher than
54% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.39 vs. KYTH: 8.21 )
KYTH' s 10-Year P/B Range
Min: 4.3   Max: 28.5
Current: 8.21

4.3
28.5
Current Ratio 9.80
KYTH's Current Ratio is ranked higher than
95% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.28 vs. KYTH: 9.80 )
KYTH' s 10-Year Current Ratio Range
Min: 1.81   Max: 11.36
Current: 9.8

1.81
11.36
Quick Ratio 9.80
KYTH's Quick Ratio is ranked higher than
95% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.74 vs. KYTH: 9.80 )
KYTH' s 10-Year Quick Ratio Range
Min: 1.81   Max: 11.36
Current: 9.8

1.81
11.36

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.56
KYTH's Price/Net Cash is ranked higher than
94% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. KYTH: 8.56 )
KYTH' s 10-Year Price/Net Cash Range
Min: 5.66   Max: 32.33
Current: 8.56

5.66
32.33
Price/Net Current Asset Value 8.56
KYTH's Price/Net Current Asset Value is ranked higher than
91% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. KYTH: 8.56 )
KYTH' s 10-Year Price/Net Current Asset Value Range
Min: 5.66   Max: 32.33
Current: 8.56

5.66
32.33
Price/Tangible Book 8.21
KYTH's Price/Tangible Book is ranked higher than
61% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.72 vs. KYTH: 8.21 )
KYTH' s 10-Year Price/Tangible Book Range
Min: 5.42   Max: 23.14
Current: 8.21

5.42
23.14

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:KYT.Germany
KYTHERA Biopharmaceuticals, Inc. was incorporated in Delaware in June 2004 under the name Dermion, Inc. It commenced operations in August 2005, and it changed its name to AESTHERx, Inc. In July 2006, it changed its name to KYTHERA Biopharmaceuticals, Inc. It is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. The Company's objective is to develop first-in-class, prescription products using an approach that relies on the scientific rigor of biotechnology to address unmet needs in the rapidly-growing market for aesthetic medicine. The Company's initial focus is on the facial aesthetics market, which comprises the majority of the aesthetic medicine market. The Company's product candidate, ATX-101, is a potential first-in-class, injectable drug currently in Phase III clinical development for the reduction of submental fat, which commonly presents as an undesirable "double chin." Based on clinical trials conducted to date, ATX-101 has exhibited significant, meaningful and durable results in the reduction of submental fat.
» More Articles for KYTH

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
KYTHERA BIOPHARMACEUTICALS INC Financials Aug 15 2014
KYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 11 2014
KYTHERA Biopharmaceuticals Submits New Drug Submission to Health Canada for ATX-101 as... Aug 11 2014
KYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 07 2014
KYTHERA BIOPHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 07 2014
KYTHERA Biopharmaceuticals Releases Second Quarter 2014 Operating Results Aug 07 2014
Q2 2014 KYTHERA Biopharmaceuticals Inc Earnings Release - After Market Close Aug 07 2014
KYTHERA Biopharmaceuticals to Release Second Quarter 2014 Operating Results Jul 31 2014
KYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 11 2014
Kythera announces FDA acceptance of ATX-101 NDA Jul 10 2014
KYTHERA Biopharmaceuticals Announces FDA Acceptance of ATX-101 New Drug Application Jul 10 2014
KYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security... Jun 09 2014
Moving Average Crossover Alert: Kythera (KYTH) May 15 2014
KYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Other Events May 13 2014
Kythera submits NDA for ATX-101 as treatment for submental fat May 12 2014
KYTHERA Biopharmaceuticals' (KYTH) CEO Keith Leonard Jr. on Q1 2014 Results - Earnings Call... May 08 2014
Kythera reports Q1 EPS ($3.18), consensus (67c) May 08 2014
KYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 08 2014
Kythera Biopharmaceuticals, Inc. (KYTH) in Focus: Stock Surges 9.9 % Apr 16 2014
KYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K/A, Unregistered Sale of Equity Securities Mar 31 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK